Episalvan clinical trials
Also written AP-101.
How each study uses episalvan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the episalvan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 1
Birken AG (6) · AL-S Pharma (2) · Memorial Sloan Kettering Cancer Center (1) · Amryt Research Limited (1) · Chiesi Farmaceutici S.p.A. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses episalvan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaRecruitingPhase 3Chiesi Farmaceutici S.p.A.NCT06917690Written as Oleogel-S10
- A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALSCompletedPhase 2AL-S PharmaNCT05039099Written as AP-101
- A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT05190770Written as Oleogel-S10
- Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis BullosaCompletedPhase 3Amryt Research LimitedNCT03068780Written as Oleogel-S10
- A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)Status unknownPhase 1AL-S PharmaNCT03981536Written as AP-101
- Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)CompletedPhase 3Birken AGNCT01807650Written as Oleogel-S10, non-adhesive wound dressing
- Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)CompletedPhase 2Birken AGNCT01294241Written as Oleogel-S10
- Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)CompletedPhase 3Birken AGNCT01657305Written as Oleogel-S10, non-adhesive wound dressing
- Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn WoundsCompletedPhase 3Birken AGNCT01657292Written as Oleogel-S10 ointment
- The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic KeratosesCompletedPhase 2Birken AGNCT00786994Written as Oleogel-S10 100 mg/g
- Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor SitesCompletedPhase 2Birken AGNCT01294254Written as Oleogel-S10